Some studies shown angiotensin II receptors blockers (ARBs) might increase the risk of developing postmenopausal osteoporosis by blocking the TGF-β1 pathway, which has been shown to be important in bone mass maintenance (Akinci et al., 2007; Edwards et al., 2010; Faraji et al., 2016; Gazit et al., 1998). Here, TGFB1 is linked to postmenopausal osteoporosis.